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OPEN
ORIGINAL ARTICLE
Convergent evidences from human and animal studies
implicate angiotensin I-converting enzyme activity in cognitive
performance in schizophrenia
A Gadelha1,5, AM Vendramini2,5, CM Yonamine1,2, M Nering2, A Berberian1, MA Suiama2, V Oliveira3, MT Lima-Landman2, G Breen4,
RA Bressan1, V Abílio1,2 and MAF Hayashi1,2
In schizophrenia (SCZ), higher angiotensin I-converting enzyme (ACE) levels have been reported in patient’s blood and
cerebrospinal ﬂuid (CSF). Hereby, we propose to explore whether the ACE activity levels are associated to cognitive performance in
SCZ. Seventy-two patients with SCZ or schizoaffective disorder diagnosis, and 69 healthy controls (HCs) underwent a cognitive
battery with parallel collection of peripheral blood samples to measure ACE activity. Signiﬁcant higher ACE activity levels were
conﬁrmed in the plasma of SCZ patients compared with HCs (Student’s t=− 5.216; Po0.001). ACE activity signiﬁcantly correlated to
Hopkins delayed recall measures (r=− 0.247; P= 0.004) and Hopkins total (r=− 0.214; P= 0.012). Subjects grouped as high ACE
activity (above average) had worse performance compared with low ACE activity level group for Hopkins delayed recall measure,
even after correction for clinical condition, age, gender and years of education (P= 0.029). The adjusted R squared for this ﬁnal
model was 0.343. This result was evident only comparing extreme groups for ACE activity, when splitting the sample in three
groups with similar number of subjects. To clarify this ﬁnding, we performed an evaluation of the cognitive performance of
transgenic mice with three copies of ACE gene in novel object recognition (NOR) test, which showed that such animals presented
impairment in NOR (Po0.05) compared with two copies of wild-type animals. The results observed in SCZ patients and animal
model suggest both the association of ACE to cognitive deﬁcits in SCZ. This ﬁnding may support the evaluation of novel treatment
protocols and/or of innovative drugs for speciﬁc intervention of cognitive deﬁcits in SCZ envisioning concomitant ACE activity and
behavior evaluations.
Translational Psychiatry (2015) 5, e691; doi:10.1038/tp.2015.181; published online 8 December 2015
INTRODUCTION
The renin–angiotensin system (RAS) is viewed as an important
regulator of blood pressure and body ﬂuid balance, although
many other functions in the central nervous system have been
related to RAS, including several associations with psychiatric
diseases and cognitive functions.1–6 Several lines of evidence
support a role for RAS in schizophrenia (SCZ). First, the regulatory
effects of RAS on brain dopamine pathways.7,8 Second, the
speciﬁc activation of the angiotensin type 2 receptor in neuronal
cells is able to induce neurite outgrowth and elongation, to
modulate neuronal excitability and cellular migration, affecting
therefore, the synapse plasticity and neurodevelopment, as
reviewed.9 Third, the key component of RAS, that is, the
angiotensin I-converting enzyme (ACE), although primarily studied
owing to its ability to convert angiotensin I (Ang I) into the
hypertensive peptide angiotensin II (Ang II),10 is also capable to
cleave peptides as neurotensin and substance P, which were
associated with SCZ, as independently reported by different
groups.11–13
The ﬁrst study of ACE in SCZ reported a reduction in the enzyme
activity in the basal ganglia of postmortem brain of SCZ patients
compared with healthy controls (HCs) that was not replicated
later.14,15 Also in studies of cerebrospinal ﬂuid (CSF) of patients,
paradoxical ﬁndings can be found, as both reductions and
increases in ACE activity levels in CSF of SCZ patients were
described.16,17 Wahlbeck and colleagues18,19 also suggested that
ACE activity levels in CSF may be correlated to the length of illness
and to the use of antipsychotics. Finally, using a smaller sample,
Baskan et al.20 reported a signiﬁcant increase in ACE protein level
in the serum of SCZ patients compared with HCs.
The ACE gene, located on chromosome 17q23, has a well-
studied insertion/deletion polymorphism resulting from the
presence or absence of a 287-base pairs fragment in the 16th
intron of ACE gene, in which the presence of D-allele is associated
with a higher ACE activity in serum.21,22 In a recent report, we
showed that ACE activity levels in plasma were higher in patients
with SCZ and the differences between the observed ACE activity
and the expected mean values of each genotype groups were the
best predictor for the clinical status (that is, patient vs HCs).23
Interestingly, higher ACE activity levels were also previously
reported in Alzheimer’s and Parkinson’s diseases, and several lines
of evidence suggested a role for RAS in cognitive functions,
especially memory.5,24,25 Ang II administration seems to interfere
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with cognitive performance in memory tests in animal models,
whereas ACE inhibitors and angiotensin type 1 receptor
antagonists improve cognitive processing in both humans and
animal models.24–27 There are several evidences for the Ang II
action in the central nervous system associated to cognitive
functions, more speciﬁcally to memory processing.28 However, the
role of Ang II is still controversial, with some studies suggesting an
amnesic effect,29–31 whereas others propose that Ang II is able to
improve memory.32,33
Cognitive deﬁcits are a central feature of SCZ and major
determinants of functional impairments, with more than 75% of
patients depicting signiﬁcant cognitive impairment.34,35 Several
domains are affected, but the effects on executive function and
memory are usually the most prominent.36
Therefore, in this study, we aim to clarify whether ACE activity
levels in the plasma of SCZ patients and HCs are associated to
cognitive performance in a neuropsychological battery. In
addition, we also conducted behavioral evaluations of cognitive
function of transgenic mice carrying three copies of the ACE
gene,37 aiming to verify the inﬂuence of higher expression levels
of the ACE in cognitive processing, and ultimately aspiring the
comparison of the data from human and animal models.
MATERIALS AND METHODS
Study in patients with SCZ
Study participants. In this study, 72 patients with SCZ or schizoaffective
disorder diagnosis and 69 HCs, aged from 18 to 65 years fulﬁlling the
inclusion and exclusion criteria and that completed the neurocognitive
battery, were enrolled. All patients were enrolled in the SCZ Community
Treatment Program (PROESQ) run by the Universidade Federal de São
Paulo (UNIFESP) for at least 1 year. The inclusion criteria were the diagnosis
for SCZ or schizoaffective disorder according to DSM-IV. This sample is part
of a larger sample enrolled to multimodal research on SCZ. All the subjects
that fulﬁlled inclusion and exclusion criteria for the current analyses were
included.
HC volunteers were selected, matching by age, gender and educational
level, from a governmental unemployment agency. Controls were ﬁrst
screened by telephone for psychiatric diagnosis and then invited to a face-
to-face, full psychiatric interview. Inclusion criteria were no current or
lifetime psychiatric diagnosis, and absence of family history of psychosis in
ﬁrst- and second-degree relatives.
Exclusion criteria for both groups were a diagnosis of arterial
hypertension, use of any antihypertensive medication, for example,
propranolol or lack of consensus diagnosis.
The Structured Clinical Interview for DSM-IV was performed for both
patients and HCs by trained psychiatrists to assess the psychiatric
diagnosis. A questionnaire adapted from the Structured Clinical Interview
for DSM-IV screening questions for each diagnosis was used to investigate
the family history of mental disease in ﬁrst and second degree, information
was collected by patient and accompanying relative. The clinical
assessment for patients also included the Positive and Negative Syndrome
Scale and Global Assessment of Functioning. For the diagnosis, we used all
the available information including medical records.
This study was previously approved by the Research Ethics Committee
of UNIFESP (CEP No. 1883/10). Written informed consent was obtained
from all the participants recruited and clinical and laboratory investigations
were strictly conducted according to the principles expressed in the
Helsinki Declaration.
Neuropsychological tests: Eight tests, assessing different aspects of
executive functions, working memory and verbal memory, were adminis-
tered. Intelligence quotient (IQ) was also measured for all the subjects. In a
previous study, the differences observed in the performance of these tasks
allowed a good discrimination between subjects with SCZ and HCs.38
Assessments were not blinded for case–control status. Well-established
and widely used neuropsychological tests used in SCZ research were used
here and they are listed and shortly described below:
Working memory/updating—Letter memory task (adapted from Morris
and Jones39)—single letters were presented serially to the participants
who were instructed to create a new string of letters by mentally adding
the most recently presented letter, dropping the third letter back, and then
reciting the new string of two letters aloud. This instruction was given and
doubled-checked for understanding to guarantee the participants'
continuous updating.
—Keep track task (adapted from Yntema40)—initially, several target
categories were shown to the participants on the computer screen. Fifteen
words, including two or three examples from each of the target categories
(animals, colors, countries, distances, metals and relatives) were verbally
presented in both serial and random orders, while the target categories
remain at the bottom of the computer screen. The subject was ﬁrst asked
to remember the last word presented in each of the target categories, and
then to say his/her answers aloud at the end of the trial.
Inhibition—Victoria Computerized Stroop Test41—the test was com-
posed of three parts, each comprising 24 stimuli. In the ﬁrst part, the
subject was asked to read the word that appears in the computer display
and the stimuli were the name of one of four chosen colors (that is, yellow,
blue, green or red) written in capital black font. In the second part, colored
circles were displayed in the screen for 40ms, and the participants have to
name the color of the circle as fast as they can, aiming to provide a
baseline measure for the analysis of errors and reaction times. In the third
part, the subjects were asked to read the color name, but the stimuli were
divergent, that is, the word was displayed for 40ms in a color different
from the color names. The scores for reaction time and for the number of
correct answers were based on the subtraction between the mean results
obtained in the third and second parts of this test.
Set-shifting tasks—trail making test42—participants were asked to
complete two tasks, one requiring to draw lines to connect circled
numbers in a numerical sequence, and the other requiring to connect
circled letters in alphabetical order. The outcome variable was the mean of
the total time taken to complete the two conditions minus the total time
taken to complete the last phase of the task.
—Plus–minus task (adapted from Jersild43)—three lists of 30 two-digit
numbers were presented. On the ﬁrst, participants need to add 3 to each
number. On the second, they have to subtract 3. On the third, they were
required to alternate between adding and subtracting 3. The outcome was
the mean of the total time taken to complete the two ﬁrst phases minus
the total time taken to complete the third phase.
—Letter–number task (adapted from Rogers and Monsell44)—a letter–
number pair is presented in one of four quadrants on the computer screen.
Subjects have to indicate whether the number was odd or even, when the
pair was presented in any of the top two quadrants. Then, they have to
indicate whether the letter presented in the bottom two quadrants was a
consonant or a vowel. Finally, stimuli were presented in all the four
quadrants, and the participants have to shift between these two types of
operations. The outcome measure was the mean of the total time taken to
complete two ﬁrst phases minus the total time taken to complete the
last phase.
Verbal learning and memory—Hopkins verbal learning task revised
(HVLT-R)45 or Hopkins delayed recall—participants were requested to read
the same list of words three times, and each time they are asked to repeat
as many words as they could recall. In this study, we used only the word-
list learning score. After 30min, they were asked to recall the list again;
allowing the delayed recall or evocation measure.
Complex executive functions—The Wisconsin card sorting task with 64
trials46—participants were requested to match cards presented with any
one of four reference cards shown on a table. They were instructed to sort
the cards into piles under the reference cards, according to categories that
must be perceived by them. Response cards could be matched on color,
shape or number. Once the participant made 10 consecutive correct sorts,
the sorting principle changed. The score of interest was the number of the
perseverative errors.
Non-verbal intelligence test—The non-verbal intelligence task (R-1)47
was developed to allow measurement of intelligence in low-literacy
populations. This test is highly correlated with the Raven's progressive
matrices test (r=0.76, P=0.001) and was chosen owing to the high
frequency of illiteracy found in the population of Brazilians with SCZ.
Direction of results. For Hopkins measures, higher values indicate better
verbal learning and memory retrieval. For all the other tests, higher values
indicate worse performance.
Blood samples. Blood samples were collected from all the subjects into
sodium heparin vacuum tubes BD Vacutainer (BD Medical—Pharmaceu-
tical Systems, Franklin Lakes, NJ, USA). The samples were then centrifuged
at 1500–2000 g for 10–15min, at room temperature, to recover the plasma,
which was then stored at − 20 °C in microcentrifuge plastic tubes (Axygen,
Union City, CA, USA) until use. The plasma was carefully removed with a
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transfer pipette without disturbing the white blood cells layer. Although
the suggested procedure is to fractionate the blood as soon as possible
after collection, some samples were kept at 4 °C up to 24 h after blood
collection and then centrifuged for plasma recovery, with no detectable
inﬂuence in the measured enzymatic activity (data not shown). The stored
plasma samples were defrosted in wet ice soon before the activity
measurements as follows.
Activity measurements. The ACE activity in human plasma samples of HC
volunteers and SCZ patients were measured by ﬂuorometry, using the
FRET peptide substrate Abz-FRK(Dnp)P-OH.48 The researcher responsible
for the measures was masked for the group of the sample for humans and
animals. Hydrolysis of the substrate (10 μM), at 37 °C, was monitored by
measuring the ﬂuorescence in a Shimadzu F-7000 spectroﬂuorometer at
λem= 420 nm and λex = 320 nm. A 96-wells plate containing 100 μl of
substrate solution (50mM Tris-HCl pH 7.4 and 100mM NaCl buffer) in each
well was placed in a thermostatically controlled cell compartment for
5 min, before the addition of the plasma samples. The increase in
ﬂuorescence (arbitrary ﬂuorescence units) with time was continuously
recorded for 5–10min, both in the absence and in the presence of the ACE
inhibitor lisinopril (Sigma Aldrich, St. Louis, MO, USA). The measured ACE
activity is the rate of hydrolysis in the absence of the speciﬁc inhibitor
minus the rate determined in the presence of the inhibitor. The average
ACE activity in the human plasma was determined by averaging the ACE
activities of three (triplicate) measurements for each sample, and then if
these values variations were higher than 5% from each other, new
measurements (at least two more measures, for example, duplicates) were
performed to assure that the ﬁnal average for all samples used in the
experiment were not because of any technical inﬂuence.
Animal study
Animals. To investigate the role of ACE, adult male C57BL/6J mice
genetically engineered carrying a duplication of the ACE locus on
chromosome 11 were used. These mice carry three functional ACE gene
copies (+/++ or three copies). Control animals consisted of wild-type
C57BL/6J mice (+/+ or two copies). Identiﬁcation of genetically modiﬁed
offspring was performed at 21 days of age, by PCR ampliﬁcation of DNA
isolated from ear biopsies. All the animals were housed under conditions of
controlled temperature (20–23 °C) and lighting (12 h light/12 h dark cycle,
lights on at 0700 h). Food and water were available ad libitum throughout
the experiments. No randomization was used. All the experiments were
performed in accordance with the Guide for the Care and Use of
Laboratory Animals of the USA National Institutes of Health (Bethesda, MD,
USA). All the experiments with animals were approved by the ethical
committee of the Universidade Federal de São Paulo (UNIFESP), CEP No.
0336/12.
Behavioral tests. Aiming to provide convergent evidences from both
human patients and animal model studies for the association between ACE
activity and cognitive deﬁcits, we elected to the novel object recognition
(NOR) test,49 which is a widely used model for the investigation of short-
and long-term memory performance.
This test is based on the spontaneous tendency of rodents to spend
more time exploring a novel object than a familiar one.50–52 The choice to
explore the novel object reﬂects the use of learning and memory
recognition. During habituation, the animals are allowed to explore an
empty arena. Twenty-four hours after habituation, the animals are exposed
for 5 min to the familiar arena with two identical objects (A + A) placed at
an equal distance. After 1 h, the animal is returned to the apparatus, which
now contains the familiar object and a novel object (A + B) to test short-
term recognition memory. The next day, the mice are allowed to explore
the open ﬁeld in the presence of the familiar object and a novel object (A +
C) to test long-term recognition memory. Animals were recorded by a
video camera placed above the apparatus and the time spent exploring
each object was registered using the animal video-tracking software
Anymaze (Stoelting, Wood Dale, IL, USA). The researchers were blind to the
genetic background of the animals.
Randomization was not performed as the animals with different genetic
background were not further divided into groups submitted to any
additional intervention.
Analysis of the data: For measuring the mean differences between SCZ
patients and HC groups, a two-independent-samples t-test was used. No
signiﬁcant difference on variance was found for the following measures
between groups: ACE activity, Hopkins total, Hopkins delayed recall, keep
track test. Signiﬁcant differences on variance were observed for the other
cognitive tasks (data not shown). For this reason, we chose nonparametric
correlations (Spearman’s coefﬁcient) to investigate the possible associa-
tions of ACE activity and cognitive tests.
The whole sample was grouped on the basis of the ACE activity levels in
three groups with similar number of subjects as: high (13.7 ± 2.0 nMmin− 1),
intermediate (9.9 ± 0.8 nMmin− 1) and low ACE (5.4 ± 2.0 nMmin− 1). We
performed a General Linear Model to compare the high and low groups,
for age, sex and IQ as covariates. The choice for three groups was to allow
the comparisons between the extreme groups.53 One advantage for
comparing extreme groups is that the overlap between the measures can
be reduced, and this would be inevitable if one uses two samples divided
by the whole sample median. Aiming to avoid that the result represents
solely an effect of distribution of case and control in the groups, clinical
status was used as covariate.
In all the adjusted models, we ﬁrst included age, sex and IQ as
covariates, and then, the clinical condition was included to clarify whether
the effects could be better explained by the ACE activity levels or by case/
control-associated differences.
For the animal model results, normal distribution was conﬁrmed by the
Kolmogorov–Smirnov test and the homogeneity of variance was revealed
by the Levene’s test. A repeated-measures analysis of variance was
performed for the NOR (within factor = object 1 and 2, and between
factor = genetic background) followed by paired-sample t-test. The
sample size estimation considered the following parameters: under an
analysis of variance (repeated measures, within–between interaction
(F-distribution)), alpha error probability, power (1−β error probability),
total sample size of 24 allocated in two different groups (N= 12),
correlation among repeated measures at least equal to 0.5 and
nonsphericity correction equal to 1 result to a minimum detectable effect
size of 0.299. Such effect size is considered by Cohen54 as moderate.
The Po0.05 was used as a criterion for statistical signiﬁcance. Sidak
procedure was adopted to estimate the corrected P-value for multiple
comparisons.
Data analyses were performed with the Statistical Package for Social




Subjects' description. The mean age of the whole sample was 33.7
years (s.d. = 9.3). No differences were observed for sex, age or
educational level between SCZ patients and HC groups (Table 1).
Mean duration of illness for patients was 12.4 years (s.d. = 7.1).
Enzymatic activity of SCZ patients and HCs. ACE activity mean
value was signiﬁcantly higher for SCZ patients (11.0 ± 3.4 -
nMmin− 1) compared with HCs (7.9 ± 3.7 nMmin− 1; Student’s
t=− 5.216; Po0.001). No signiﬁcant correlation was observed
between enzymatic levels and total Positive and Negative
Syndrome Scale (Spearman's rho =− 0.92; P= 453) or global
functioning (Spearman's rho = 0.31; P= 801). No correlations in
enzymatic levels were observed in the whole sample with age
(Spearman's rho = 0.057; P= 0.504), gender (t= 1.87; P= 0.064),
years of education (Spearman's rho =− 0.056; P= 0.509). No
signiﬁcant difference on ACE activity level was observed for
Table 1. Sociodemographic characteristics
Patients (n= 72) Healthy
controls (n= 69)
Statistics
N (%) N (%) Test-value P-value
Gender Male 50 (69.4) 44 (63.8) 0.511 0.475
Female 22 30.6 25 31.2
Educational
level
Years 72 (11.11) 69 (11.33) 0.478 0.634
Age, mean Years 72 (33.19) 69 (34.22) − 0.656 0.513
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smoking or number of cigarettes per day (Chi-squared = 4.9;
P= 0.179).
Cognitive performance differences between SCZ patients and
HCs: Patients had nonsigniﬁcant lower IQ mean level. Most
cognitive measures showed signiﬁcant better results for subjects
from the HC group, with the exception for the letter memory test
(which allow evaluating the updating; Table 2). We checked in the
patients’ group the effect of antipsychotics using dose equivalents
for chlorpromazine. The only signiﬁcant association was found for
the letter memory test (Spearman’s rho = 0.286; P= 0.015).
Cognitive performance and ACE activity association: Aiming to
determine the inﬂuence of the measured enzymatic activity on
the cognitive performance, the statistical analysis was performed
for both the whole sample and for the separated groups.
Considering the whole sample, signiﬁcant correlations for memory
(Hopkins delayed recall; Pcorr =− 0.25; P= 0.003), verbal learning
(Hopkins total; Pcorr =− 0.219; P= 0.010) and inhibition (Stroop;
Pcorr = 174; P= 0.042) correcting for age, gender and IQ were
found. Only Hopkins delayed recall remained signiﬁcant consider-
ing P-value corrected for multiple testing (Sidak method; P-value
threshold 0.006). After the addition of clinical condition (patient or
HCs) as covariate, the result was no longer signiﬁcant (r=− 0.76;
P= 0.377) (results are shown in Table 3). When performing
correlations for each group separately, we did not ﬁnd any
signiﬁcant result (data not shown). The scatter plots of Hopkins
delayed recall and ACE activity clearly show marked differences in
the pattern of distribution between SCZ patients and HCs, which
may explain the results for correlations considering the whole
sample and each group separately (Figure 1).
Therefore, the whole sample was initially divided in two groups
using the median ACE activity. Then we performed a general linear
model comparison between the extreme groups (high vs low ACE
activity groups) for each cognitive test using IQ, gender and age as
covariates. Signiﬁcant differences were observed for Hopkins total
(Z= 4.836; P= 0.030); Hopkins delayed recall (Z= 9.870; P= 0.002)
and Stroop (Z= 10.301; P= 0.002). After adding clinical condition
as a covariate, none of these results reached signiﬁcance
considering the P-value threshold corrected for multiple compar-
isons, although Stroop remained signiﬁcant (Z= 4.493; P= 0.036).
Then, we split the sample in three groups composed by similar
number of subjects as high, medium and low ACE activity
categories. In this set of analyses, only Hopkins delayed recall
remained signiﬁcant (P= 0.029), although a trend was observed
for inhibition (Stroop; P= 0.084). The adjusted R squared for the
ﬁnal model with Hopkins delayed recall was 0.343. This ﬁnal result
would not be considered signiﬁcant considering the threshold for
multiple comparisons (P= 0.006). Therefore, at this point, aiming
to better understand our preliminary data in humans, we looked
for data on an ongoing animal study validation. We additionally
checked the potential effect of antipsychotics on the result and
found no signiﬁcant difference on antipsychotic’s dose equiva-
lence for ACE groups, dichotomized (t= 0.112; df = 70; P= 0.911) or
split in three groups (Z= 1.72; df = 2; P= 0.187).
Animal study. For NOR, repeated-measures analysis of variance
showed a signiﬁcant effect of novel objects (within subject; F
(1.22) = 11.692; Po0.05) and an interaction between this factor
and the genetic background (between factor; F (1.22) = 12.166;
Po0.05). Paired-samples t-test showed that transgenic mice did
not preferentially explore the novel object in either sessions (at 1
and 24 h after familiarization), whereas control group spent more
time exploring the novel object at 1 h (Figure 2a) and 24 h
(Figure 2b) after the training session (t (11) =− 7.152, − 4.485;
Po0.05, respectively). During the training session, with two
identical objects, no signiﬁcant difference in the time of
exploration was observed (Figure 2c).
DISCUSSION
Our results suggest that ACE may have a role in cognitive deﬁcits
observed in patients with SCZ. First, we found higher ACE activity
levels associated to a worse performance in verbal memory test
for a sample comprising patients with SCZ and HCs. In parallel, we
showed that mice with three copies of ACE genes displayed
impairment in one cognitive test associated to short- and long-
term memory. In addition, there was a signiﬁcant difference in
ACE activity and cognitive performance on several tests between
SCZ patients and HCs.
Cognitive functioning is a core feature of SCZ. Approximately
80% of patients are clinically impaired in at least one cognitive
Table 2. Differences in tests performance between patients and
healthy controls
Cognitive domain Test-value P-value
Working memory/updating
Letter memory task − 1.784 0.0740
Keep track task − 4.117 o0.0001
Inhibition
Stroop − 4.008 o0.0001
Set-shifting tasks
Trail making test − 3.828 0.0002
Letter–number task − 5.494 o0.0001
Verbal learning/memory
Hopkins total − 6.422 o0.0001
Hopkins delayed recall − 5.585 o0.0001
Complex executive function
WCST-CAT − 1.600 0.1100
Abbreviation: WCST-CAT, Wisconsin card sorting task category score.
Table 3. Correlation between ACE enzymatic level and results of
cognitive tests (adjusted for age, sex and IQ)




Letter memory task − 0.035 0.682 0.026 0.767
Keep track task − 0.138 0.108 0.000 0.998
Inhibition
Stroop 0.174 0.042 0.042 0.627
Set-shifting tasks
Trail making test 0.010 0.906 − 0.086 0.318
Letter–number task 0.118 0.169 − 0.067 0.437
Verbal learning/memory
Hopkins total − 0.218 0.010 − 0.008 0.925
Hopkins evoc − 0.250 0.003 − 0.076 0.377
Complex executive function
WCST-CAT 0.021 0.803 −0.049 0.569
Abbreviations: ACE, angiotensin I-converting enzyme; WCST-CAT, Wiscon-
sin card sorting task category score.
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domain.55 Cognitive performance was the best predictor of
functional outcome for patients with SCZ.56 Moreover, cognitive
decline starts before the onset of psychosis,57 suggesting that
cognitive impairments might reﬂect the neurodysfunction process
that underlies SCZ development rather than only disease
progression processes.58,59 Almost all cognitive functions are
impaired at heterogeneous levels in different studies for each
cognitive domain, in part, by methodological issues, but most
probably also owing to true differences between the patients.60 In
such context, verbal memory is among the most impaired
cognitive domains in SCZ and unaffected siblings.36,61 As
expected, differences in cognitive performance between SCZ
patients and HCs were observed for most tests used here.
Hopkins verbal learning test or Hopkins delayed recall is a three-
trial list learning, and free recall task comprising 12 words, in
which four words are from different semantic categories.45 The
immediate recall can be considered a test for verbal learning or
short-term memory, whereas the later free recall is a long-term
verbal memory test, in which the information, after being out of
consciousness ﬂow need to be retrieved. In our sample, the
association of ACE was stronger for later recall, suggesting an
association to long-term memory.
The ﬁrst issue to be considered is that ACE activity and Hopkins
delayed recall measures were both highly different between SCZ
patients and HCs (Figure 1). Therefore the signiﬁcant correlation
observed between them can reﬂect a statistical artifact. None-
theless, the differences on cognitive tests performance of patients
and HCs, considering Hopkins delayed recall (t=− 5.585) as
parameter, were higher for the Hopkins total measure (t=− 6.422)
and similar to the Letter–number task (t=− 5.494). Thus, the
results are not fully explained by the observed difference between
patients and controls. Furthermore, there is a known previous
speciﬁc association between ACE and memory.24 To better
understand whether this was an effect of being a patient of
having higher ACE levels, the sample was divided in groups based
upon ACE activity levels, and we found that the Hopkins was
signiﬁcantly different between high- and low-activity groups, even
correcting for case status (P= 0.029). The scatter plots of Hopkins
vs ACE measures suggest that the marked difference between
patients and HC explain why the correlation is signiﬁcant only with
the whole sample, whereas the extreme group comparison
reinforce a true association of ACE and memory, irrespective of
clinical status. At this point, however, the results with humans
must be considered with caution, because some did not survive
considering the multiple comparison-adjusted P-value, which
suggested not enough power to detect true effects. One
additional limitation to the interpretation of the results is the
use of antipsychotics in the patients group. Using a dose
equivalence approach, the results seemed not to be signiﬁcantly
affected by antipsychotics, although we cannot rule out this
possibility, as our controls were non-medicated.
The NOR test is based on the spontaneous tendency of rodents
to spend more time exploring a novel object than a familiar one.
The choice to explore the novel object reﬂects the use of learning
and recognition memory.49 Transgenic animals with three copies
showed a deﬁcit in the recognition test performed at 1 and 24 h
after the training session, indicating short- and long-term memory
deﬁcits (Figure 2). It has been previously described that ACE
activity in these animals are increased to 144% compared with
animals with two copies.37 This increase is not accompanied by
changes in blood pressure.37,62 Our animal model adds novelty to
the current literature as it shows that differences in ACE availability
can induce cognitive effects, which is in good agreement with the
results on ACE and cognition in other neuropsychiatric diseases
and different animal models. In fact, treatment with ACE inhibitors,
specially using centrally active compounds (that is, perindopril or
captopril), reduced the risk to develop both Alzheimer's disease
and vascular dementia in patients,27,63,64 and this effect was
signiﬁcantly independent of the indication due to hypertension.65
In Alzheimer's disease animal model, perindopril, but not imidapril
or enalapril (non-centrally active ACE inhibitors) reduced the
cognitive impairment, independently of its antihypertensive
effects.66,67 Using the same NOR test, Yamada et al.26 found that
perindopril improves the cognitive impairment in animal model of
vascular dementia. Current literature on animals and humans
suggest that the effects of ACE on cognition are independent of
blood pressure variation, but as we did not directly measure the
blood pressure of animals and humans in the current study, we
cannot completely exclude this possibility, which need to be
addressed in future replications.
The precise mechanisms underlying the impaired cognition
observed for three-ACE copy mice are not completely clear at this
point. However, one might consider the ACE roles in RAS, in which
an increase in ACE activity could lead to an increase of Ang II
which, in turn, was associated in several studies to impairments in
learning and memory.68–70 The injection of Ang II in rat
hippocampus inhibits the enhancement of long-term memory.71
In another study, the Ang II caused impairment in spatial memory,
affecting the acquisition, consolidation and recall of memory, and
signiﬁcantly reduced acetylcholine levels without affecting the
Figure 1. Correlations for memory (evaluated by Hopkins measures) and ACE activity in schizophrenia (SCZ) patients (a) and health controls
(HCs) group (b). The Hopkins plot with patients and HCs together allow to observe a clear trend for lower Hopkins delayed recall and higher
ACE activity in SCZ patients compared with HCs (c). ACE, angiotensin I-converting enzyme.
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levels of acetylcholinesterase.70 Furthermore, the use of
angiotensin type 1 blockers or ACE inhibitors were shown to
improve memory and reverse cognitive deﬁcits in animals.67,68
However, as we did not measure the angiotensin compound
levels, we cannot state that the observed results are only
attributable to RAS. In fact, ACE is a ubiquitously expressed
enzyme that can catalyze the cleavage of several other substrates
known to impact the cognitive performance, such as the
substance P72 and neurotensin.73 Furthermore, animal studies
have shown that ACE inhibition improves memory function and
prevents the impairment associated with cholinergic hypofunc-
tion, oxidative stress and the deposition of β-amyloid.70,74–76 One
additional possibility is through the association between ACE and
dopaminergic neurotransmission. Indeed, acute and chronic
cocaine administration induced a signiﬁcant increase of ACE
activity and gene expression in the rat prefrontal cortex and
striatum, whereas ACE inhibitors showed a decrease in dopamine
release.5,6 Furthermore, both striatal and prefrontal function have
been associated to performance on Hopkins delayed recall.77
Dopamine and glutamate systems manipulations can generate
robust impairments in NOR.52 So, the dopamine-RAS78 interplay
could explain ACE link to SCZ and cognitive deﬁcits, representing
it as a promising target to further investigation. Overall, the
different described pathways can link ACE and cognition, but how
this truly happens for SCZ needs to be further investigated.
Whenever investigating animal models, one major issue is
whether the results of the tests can be considered a correct
approximation to the human behavior and cognitive performance.
At this point, the translational approach suggesting convergence
to memory impairments with higher ACE activity levels reinforce
our ﬁndings, although with some cautions. Otherwise, the
National Institute of Mental Health Measurement and Treatment
Research to Improve Cognition in Schizophrenia proposed both
the Hopkins Verbal Learning—Immediate recall and NOR as part
of consensual batteries, respectively in humans and animals, for
the cognitive investigation in SCZ.79,80 Although the tests are
suggested to investigate SCZ, they do not measure exactly the
same construct (verbal memory in humans vs recognition memory
in animals) and there are differences in the timing of outcome
measures (30 min for Hopkins delayed recall vs 24 h for NOR). So,
there are some limitations on the translational approach adopted
that prevent us to conclude, but not to suggest the association of
ACE and memory in SCZ.
In conclusion, our study demonstrates a previously unreported
association between ACE and cognitive measures in patients with
SCZ. We show then that the modulation of ACE gene load is
associated with cognitive performance in mice. Although previous
studies have focused on Ang II, we provide here evidences that
ACE can, by itself, contribute to cognitive phenotypes. These
results are especially relevant considering that until now, there is
no effective pharmacological treatment to cognitive deﬁcits in
SCZ. Future studies would clarify whether centrally active ACE
inhibitors could be an add-on strategy on SCZ.
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Figure 2. Novel object recognition test. Percentage of time spent
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Object recognition after 1 (a) and 24 h (b) after training (c). As
appropiate, repeated-measures analysis of variance followed by
paired-sample t-test were performed. Data are reported as mean± s.
e.m. *Po0.05 compared with the time exploring the familiar object.
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